CompanyOverview\|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.
Everest Medicines has dosed the first subject with EVM16, the company’s personalised mRNA cancer vaccine, in the EVM16CX01 ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
mRNA-4157, under study in collaboration with Merck, also shows potential across various cancerous tumor types. This diverse pipeline reflects the company’s ability to divulge its mRNA technology ...
Dr. Vinod Balachandran says mRNA vaccines could stimulate the immune system to recognize and attack pancreatic cancer cells. An experimental approach to treating pancreatic cancer with the messenger ...
and mRNA-4157/V940 (individualized neoantigen therapy). mRNA-4157 is an important candidate garnering investors’ attention. It is being developed in partnership with Merck MRK. Moderna/Merck is ...
It is evaluating multiple candidates in late-stage studies, including mRNA-1647 (cytomegalovirus [CMV] vaccine), mRNA-1010 (influenza vaccine) and mRNA-4157/V940 (individualized neoantigen therapy).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback